US tariff policy changes are forcing European pharmaceutical firms to cut drug prices or face new barriers. The European industry warns of growing risks to investment and innovation. The sector now trails China and the US in new treatments.
European pharmaceutical companies are under new strain as changes in US tariff policy force them to choose between lowering drug prices for the American market or facing trade barriers. The Federation of European Pharmaceutical Industries and Associations (Efpia) has warned that these measures could further weaken Europe’s position in medical innovation and investment.
The main issue is the US administration’s push for Most Favoured Nation (MFN) pricing, which requires drugmakers to match the lowest global prices or face tariffs. Twenty-six major pharmaceutical firms have already signed agreements with the US to avoid these tariffs, agreeing to reduce their prices in the American market. This could have knock-on effects in Europe, where medicine costs may rise and access to new treatments could become more limited.
In April 2026, the US announced a 100% tariff on patented pharmaceuticals, with a reduced 20% rate for companies localizing production, and a potential 0% for those signing MFN pricing agreements.
Efpia says there is still no clear evidence on how these US policies will affect European patients, drug availability, or national healthcare budgets. The outcome will depend on how companies respond and what steps European governments take. Uncertainty is growing, especially after a recent study in The Lancet suggested that European drug prices could rise as a direct result of the US measures.
Europe’s pharmaceutical sector has already lost ground. Efpia notes that the continent now attracts much less global investment, runs only half as many clinical trials as it did ten years ago, and has slipped to third place—behind China and the US—in discovering new treatments. This decline affects both patients and the wider economy.
From September 1, 2026, the EU-US trade framework specifies that only MFN tariffs will apply to generic pharmaceuticals and their ingredients, while stricter tariffs remain for patented drugs. This distinction means European companies face the greatest risk in the innovative medicines segment, especially as manufacturers may shift pricing strategies across markets.
The MFN pricing policy, intended to lower costs for US consumers, could distort the global market for new medicines. Efpia warns that this may limit the worldwide availability of new drugs, especially in countries included in MFN agreements. The group says Europe needs to act to make its market more attractive to global pharmaceutical companies and to ensure that medical innovation is adopted as quickly as in other leading countries.
Despite the modeling published in The Lancet, Efpia remains cautious, noting that the study’s conclusions depend heavily on its assumptions. The group argues that Europe cannot afford to stand by as it falls further behind in pharmaceutical research and development. Targeted measures to boost competitiveness and keep investment in Europe are now urgent.
These developments reflect a broader pattern of regulatory and market changes affecting major European industries, as seen in the recent Acciona Energía takeover battle. Both cases show how outside policy changes can reshape entire sectors and force European companies to adapt or risk losing ground globally.
Europe’s pharmaceutical industry is at a turning point. The US tariff strategy is more than a trade dispute—it directly challenges Europe’s ability to compete in medical innovation. Unless European governments and industry leaders move beyond cautious statements and take concrete action, the continent risks falling further behind in global healthcare. Efpia’s warning is clear: without urgent steps, Europe’s influence in shaping the future of medicine will keep shrinking.
